Search Results
Aug 26, 2026, 10:49 ET Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
included liver (52.6%), esophagus (50.0%), and upper gastrointestinal tract (50.0%); pulmonary response rate based on the 2014 NIH Consensus Criteria lung symptom score was 23.7% (95% CI: 11.4 to 40.2).Safety: AEs occurring in ≥20% of patients included transient bilirubin elevation (81.7%)
More news about: Graviton BioScience Corporation
Aug 26, 2026, 10:41 ET Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
currently under clinical development for several cancers, including platinum-resistant/refractory ovarian cancer, recurrent non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and pancreatic cancer. In November 2023, Genelux announced that the US FDA had granted Fast Track Designation (FTD) to
More news about: DelveInsight Business Research, LLP
Aug 26, 2026, 09:17 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
Lateral Flow Assay.Nu.Q® Lung Cancer Reimbursement SubmissionLung Cancer remains the major cause of cancer-related mortality worldwide.We believe that Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians
More news about: VolitionRx Limited
Aug 26, 2026, 07:00 ET Insmed to Present at September 2026 Investor Conferences
advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and
More news about: Insmed Incorporated
Aug 26, 2026, 07:00 ET Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma
with VT3989 gives us real conviction as we prepare for the Phase 3 sTEADfast study. Despite the approval of over 35 targeted agents for other forms of lung cancer, current treatments for mesothelioma are limited to non-tumor specific agents. We have a huge responsibility to deliver this meaningful new targeted
More news about: Vivace Therapeutics, Inc.
Aug 25, 2026, 17:00 ET Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
positive Phase III study for ivonescimab in gastrointestinal tumors, following four positive Phase III results in lung cancer. The breakthrough clinical value of ivonescimab is now expanding from lung cancer to a broader range of solid tumors. We look forward to making this innovative therapy available to patients
More news about: Akeso, Inc.
Aug 25, 2026, 09:15 ET /C O R R E C T I O N -- Akeso, Inc./
expands its broad innovative oncology pipeline.B7-H3 is highly expressed in a broad range of solid tumors, including non-small cell lung cancer, small cell lung cancer, prostate cancer, esophageal cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, and glioblastoma, with limited expression
More news about: Akeso, Inc.
Aug 25, 2026, 09:00 ET Mercy and Aidoc Reveal Faster Diagnoses and Earlier Treatment for Thousands of Patients
-- When a 55-year-old woman came to Mercy for help with unexplained weight loss, neither she nor her care team were looking for a blood clot in her lung. But thanks to careful use of an emerging technology, her potentially life-changing experience is one of more than 50,000 findings highlighted in a
More news about: Mercy
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
unmet clinical need. In the EU, it obtained three additional first-line approvals for squamous non-small-cell lung cancer, esophageal squamous-cell carcinoma and non-squamous non-small-cell lung cancer. To date, serplulimab has been launched in approximately 50 countries and regions worldwide and is reimbursed
More news about: Fosun Pharma
Aug 25, 2026, 07:00 ET Brainomix to Present Five New Studies at ERS Congress Demonstrating the Potential of Quantitative CT in Interstitial Lung Disease (ILD)
Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered image analysis tool that provides automatic quantifications and visualizations of radiographic features in lung CT scans. Clinicians can use these outputs to aid in their diagnostic assessment of lung diseases."These five
More news about: Brainomix
Aug 25, 2026, 07:00 ET Altesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year
therapies targeting chronic lung diseasesATLANTA, Aug. 25, 2026 /PRNewswire/ -- Altesa BioSciences, a clinical-stage pharmaceutical company focused on addressing the impact of chronic lung diseases including COPD and
More news about: Altesa Biosciences Inc.
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
into Key Growth AreasIn oncology, Innovent has established a strong product portfolio and brand presence across core indications including lung cancer, gastrointestinal cancers and hematological malignancies. Focusing on the next-generation "IO + ADC" innovation strategy, the Company is advancing
More news about: Innovent Biologics
Aug 25, 2026, 06:06 ET Fifth Annual Screening Saves Lives: Karmanos Cancer Institute Encourages Community to Get Caught Up on Cancer Screenings This October
in Detroit, over 416 were diagnosed with cancer. That's about 1 in every 240 people. Cancers that had the highest instances in Detroit were breast, lung and colorectal – three cancers where there are routine screening recommendations designed to catch cancer in its earlier stages.Cancer Screenings
More news about: Karmanos Cancer Institute
Aug 25, 2026, 02:22 ET Fractal establishes India Business Unit to meet increasing demand from large Indian enterprises
Qure.ai, a global healthcare AI leader focused on the rapid identification and management of tuberculosis, lung cancer, and stroke (or critical health conditions). Fractal's suite of businesses consists of Asper.ai (a
More news about: Fractal Analytics Limited
Aug 25, 2026, 02:09 ET Fractal establishes India Business Unit to meet increasing demand from large Indian enterprises
Qure.ai, a global healthcare AI leader focused on the rapid identification and management of tuberculosis, lung cancer, and stroke (or critical health conditions). Fractal's suite of businesses consists of Asper.ai (a
More news about: Fractal Analytics Limited
Aug 24, 2026, 16:19 ET TGH Brooksville Performs First Cardiothoracic Surgery, Expanding Access to Advanced Heart Care in Hernando County
have access to university-based expertise, research-driven surgical techniques, leading-edge technologies and evidence-based care for complex heart and lung conditions. The cardiothoracic surgery program provides advanced surgical care for conditions affecting the heart, lungs and chest, including coronary
More news about: Tampa General Hospital
Aug 24, 2026, 14:05 ET Bitmine Immersion Technologies (BMNR) Công Bố Lượng ETH Nắm Giữ Đạt 5,85 Triệu Token, Đưa Tổng Tài Sản Tiền Mã Hóa và Tiền Mặt Lên Mức 14,9 Tỷ USD
liên kết tại đây) cho tháng 7 năm 2026. Tiêu đề của Thông Điệp này là "ETH chính là liều thuốc giải cho Thung Lũng Kỳ Lạ của Sự Giàu Có".Vào đầu năm 2026, Bitmine đã ra mắt MAVAN (Made in American VAlidator Network) – nền tảng staking chuyên biệt dành cho
More news about: Bitmine Immersion Technologies, Inc.
Aug 24, 2026, 12:35 ET UT Health San Antonio names NIH expert inaugural director of stem cell transplant and cellular therapy program
completed residency training in Germany and the United States. He completed a fellowship in hematology and medical oncology at the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute, and later earned an MBA in finance, leadership and strategy from New York University's
More news about: The University of Texas Health Science Center at San Antonio
Aug 24, 2026, 09:26 ET Brayton Purcell LLP Highlights KQED Forum Discussion on California's Growing Artificial Stone Silicosis Crisis
2019. Dozens have died, and many others have undergone or are awaiting lung transplantation.Silicosis is a progressive and incurable lung disease caused by inhaling respirable crystalline silica. The disease leads to permanent lung scarring, severe breathing difficulties, disability, and death.The
More news about: Brayton Purcell LLP
Aug 24, 2026, 09:10 ET New CU Anschutz Division of Transplant Medicine is First of Its Kind Nationally
working in close partnership with UCHealth University of Colorado Hospital, the division will bring together leading experts in kidney, liver, heart and lung transplantation with specialists in infectious diseases, endocrinology, psychiatry and other fields."CU Anschutz is creating a new model for
More news about: University of Colorado Anschutz
Aug 24, 2026, 08:55 ET Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Aug 24, 2026, 07:50 ET IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
Aug 24, 2026, 07:00 ET BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
patients with NCFB and clinicians who treat the disease an option to manage this chronic and progressive disease that can lead to permanent lung damage and lung function decline. With this approval, BRINSUPRI is now approved for use in the U.S., Europe, and Japan."Today's approval of BRINSUPRI
More news about: Insmed Incorporated
Aug 21, 2026, 09:00 ET Coreline Soft and INFINITT North America Deploy Chest CT-Based AI Reading Workflow at St. Joseph's Health
The initial deployment will focus on chest CT examinations performed for lung cancer screening, with AI pre-analysis supporting radiologists in identifying and quantitatively assessing clinically significant findings such as lung nodules. The system delivers structured results within the radiologist's
More news about: Coreline Soft
Aug 21, 2026, 08:58 ET Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
period, it has obtained approvals for three additional first-line indications—non-squamous non-small cell lung cancer (nsqNSCLC), esophageal squamous cell carcinoma (ESCC), and squamous non-small cell lung cancer (sqNSCLC) in the EU—and has been incorporated into the national healthcare or public reimbursement
More news about: Henlius